A cervical cancer vaccine has received a positive reception at the European Committee for Human Medicinal Products (CHMP).
The CHMP reviewed data of clinical trials of almost 30,000 women and found the vaccine to be efficient and well tolerated.
The vaccine is the brainchild of pharmaceutical company GlaxoSmithKline.
It is designed to enhance the immune system and protect women against cancer-causing virus types for longer.
"Today's positive opinion from the CHMP is great news for women across Europe. It is a significant step towards achieving our ambition - to provide women with protection against cervical cancer," said the Chief Executive Officer of GSK Ms Garnier.
"Coupled with the excellent clinical trial results published recently, this news is further evidence of the great potential of our cervical cancer candidate vaccine."
If the cervical vaccine is finally approved by the European Commission then it could be given the go ahead to be marketed in the coming months.